ImYoo closes seed round, grows team, and is on track to decentralize immune studies

ImYoo is on track to decentralize immune studies and kickstart research aimed at addressing actionable patient curiosities. We grew our team and launched a revised website: www.imyoo.health!

ImYoo runs Rheumatoid Arthritis (RA) workshop with patient advocates

Rheumatoid arthritis (RA) is characterized by flare ups, which can be unpredictable. However, efforts in RNA-sequencing are already predicting flares with accuracy of up to 2 weeks before the episode.

In the ImYoo RA Working Group, we ask, "How are these flares triggered?" and "Why do biologics only work for some people?" Tell us which RA questions we need to research now - your question could be our next research idea!

ImYoo partners with Jumpcode Genomics

ImYoo has partnered with Jumpcode Genomics to use Jumpcode’s RNA depletion technology to improve data quality and eliminate the uninformative sequences that were reduce the ability to gather valuable data at reasonable costs, using Jumpcode's CRISPRclean Single Cell RNA Boost Kit.

Read more at jumpcodegenomics.com:

https://www.jumpcodegenomics.com/resources/customer-stories-imyoo/